Cambrex adds new development and analytical equipment in Italy

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/suprunvitaly)
(Image: Getty/suprunvitaly)

Related tags: Active ingredient

Cambrex Corporation has announced a new investment in its research and development (R&D) and manufacturing capabilities at its site in Paullo, Milan, Italy.

According to the company, it has installed development and analytical equipment to support the development of highly potent APIs (HPAPIs), including a new 2,800-liter hydrogenator and 1,500mm diameter centrifuge.

Equipment installation and validation with be concluded by the end of 2017.

The small molecule and generic Active Pharmaceutical Ingredients (APIs) manufacturer opened the pilot plant in October 2016 at which time it said further upgrades would follow in order to support the production of Class 3/4 high potency products.

The cGMP plant can produce batch sizes from 1kg to 15kg.

Cambrex also invested $24m​ in a new Charles City, Iowa plant earlier this year. The facility is expected to be open in 2019.

The company’s High Point, NC-based facility was also expanded​ to include a new $3.2m, 11,000 square foot analytical laboratory in August. 

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers